Fibrogen Pharmaceuticals Healthcare: Ken Research
FibroGen Inc (FGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

FibroGen Inc (FGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH13844D
  • |
  • Pages: 35
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

FibroGen Inc (FibroGen) is a biotechnology company that discovers, develops and commercializes new therapeutics. The company's pipeline product portfolio includes FG-4592, an oral small molecule inhibitor of HIF prolyl hydroxylases that is used for the treatment of anemia in chronic kidney disease; FG-3019, a monoclonal antibody developed to treat duchenne muscular dystrophy, idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. Its roxadustat is supported by extensive clinical data demonstrating correction and maintenance of hemoglobin levels in multiple subpopulations of CKD anemia patients. The company conducts research and development in the fields of connective tissue growth factor and hypoxia-inducible factor. FibroGen is headquartered in San Francisco, California, the US.

FibroGen Inc (FGEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

FibroGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

FibroGen Inc, Medical Devices Deals, 2012 to YTD 2018 9

FibroGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

FibroGen Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 11

Equity Offering 12

FibroGen Raises USD374.9 Million in Public Offering of Shares 12

FibroGen Raises USD120 Million in Public Offering of Shares 13

FibroGen Raises USD168 Million in IPO of Shares 15

FibroGen to Raise USD20 Million in Private Placement of Shares 17

FibroGen Inc-Key Competitors 19

FibroGen Inc-Key Employees 20

FibroGen Inc-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Recent Developments 22

Financial Announcements 22

May 09, 2018: FibroGen Reports First Quarter 2018 Financial Results 22

Feb 27, 2018: FibroGen Announces Fourth Quarter and Full Year 2017 Financial Results 24

Nov 08, 2017: FibroGen Reports Third Quarter 2017 Financial Results 25

Aug 07, 2017: FibroGen Reports Second Quarter 2017 Financial Results 27

May 09, 2017: FibroGen Reports First Quarter 2017 Financial Results 28

Mar 01, 2017: FibroGen Reports Fiscal 2016 Financial Results 29

Corporate Communications 30

Sep 19, 2017: FibroGen Appoints Gerald Lema to Board of Directors 30

Product News 31

03/31/2017: FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS 31

Clinical Trials 32

Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease 32

Jan 30, 2017: FibroGens Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China 33

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35

List of Figures

FibroGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

FibroGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

FibroGen Inc, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

FibroGen Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

FibroGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

FibroGen Inc, Deals By Therapy Area, 2012 to YTD 2018 8

FibroGen Inc, Medical Devices Deals, 2012 to YTD 2018 9

FibroGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 11

FibroGen Raises USD374.9 Million in Public Offering of Shares 12

FibroGen Raises USD120 Million in Public Offering of Shares 13

FibroGen Raises USD168 Million in IPO of Shares 15

FibroGen to Raise USD20 Million in Private Placement of Shares 17

FibroGen Inc, Key Competitors 19

FibroGen Inc, Key Employees 20

FibroGen Inc, Subsidiaries 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

FibroGen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com